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Abstract
We present our initial experience of allogeneic stem cell transplant procedure performed between April 2004 and
August 2011 for various haematological disorders. All patients with non-malignant and malignant haematological
disorders with HLA matched donors were selected after pre-transplant workup. Ninety seven patients underwent
the procedure. Most common indications for transplant were aplastic anaemia in n = 34 (35%), followed by β-
Thalassemia major in n = 21 (21.6%) and chronic myeloid leukemia in n = 11 patients (11.3%). Primary graft failure
present was present in 2.06%. Incidence of graft versus host disease (GvHD) in our patients was 34%. After median
follow-up of five years the overall survival was 71.3% with a mean survival time of 51.2 ± 3.3 months.
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Introduction
Haematopoietic stem cell transplant is now the standard
of care in many congenital or acquired, malignant and
non-malignant haematological diseases. The last few
years have seen rapid increases in volumes of the pro-
cedure. In 2006, approximately 60,000 transplants were
performed worldwide [1]. Although the history of trans-
plant began in the late 1940s and 1950s when animal
studies revealed the ability of donor bone marrow to re-
store hematopoieis after irradiation, in Pakistan, stem
cell transplant was started in 1995[2].
In a country like ours where consanguinity prevails, β-
thalassemia major is the most common genetic haemato-
logical disorder requiring stem cell transplant as a cura-
tive treatment option [3]. Pakistan is also included in the
list of countries where prevalence of aplastic anaemia is
high. This is second most common indication for trans-
plant in our setting [4]. Apart from these two disorders,
rest of the allogeneic procedures mainly revolve around
chronic and acute leukaemia. Due to the large family
sizes, in 70% of the patients an HLA identical sibling
donor is available as compared to the western popula-
tion. Autologous stem cell transplant is mainly indicated
in lymphomas and myeloma but frequency is lower as
compared to allogeneic procedures.
With a per capita income of $1051 (2009–2010), the
affordability of stem cell transplant procedure by an
average man is prohibited by its cost which ranges from
$100,000 -$150,000. Although the cost is cheaper locally,
majority of our transplants are funded mainly by nongo-
vernmental organisations and philanthropists.
Currently, stem cell transplant is being performed in
three centres. Our centre was established in April 2004.
Initially it was a two bedded unit which was upgraded to
four bedded in 2006. With this background, we present
our initial experience between April 2004 and August
2011 of allogeneic haematopoietic stem cell transplant
for various haematological disorders.
Subjects and methods
All patients with non-malignant and malignant haem-
atological disorders with HLA matched donors were
selected for the procedure.
Pre-transplant work-up
Complete blood counts, liver and kidney function tests,
and infectious disease profile (consisting of hepatitis B
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surface antigen, hepatitis C antibody, HIV antibody,
Cytomegalovirus, Mantoux test, chest and dental roent-
genograms), along with blood grouping and coagulation
testing was performed in all donors. For patients, screen-
ing included all the above mentioned investigations along
with pulmonary function tests, echocardiography and
dental evaluation.
Stem cell mobilization
All donors were given granulocyte–colony stimulating
factor (G-CSF) at a dose of 5-10 μg/kg/twice daily for
five days prior to harvest. Patients with donors less than
five years received bone marrow only as the stem cell
source. In patients with aplastic anaemia, peripheral
blood as well as bone marrow stem cells were the pre-
ferred source. In all other conditions peripheral blood
progenitor cells only were used as the source of stem
cells.
Conditioning regimen
Patients with Thalassemia, Acute Myeloid Leukemia,
Chronic Myeloid Leukemia, Biphenotypic Leukemia and
Philadelphia negative Acute Lymphoblastic Leukemia
received Busulfan (4 mg/day for four days) and Cyclo-
phosphamide (60 mg/kg/day for two days) as condition-
ing chemotherapy. Class III thalassemic patients received
conditioning with hyperchelation protocol which con-
sisted of deferoxamine 40 mg/kg, hydroxyurea 30 mg/kg
and azathioprine 3 mg/kg daily between day-45 and day-
11 before transplantation. From day-17 till day-13, Flu-
darabine was administered at a dose of 20 mg/m2/day.
On day-10, Busulfan was started at 1 mg/kg thrice daily
for four days (total 14 doses) followed by cyclophospha-
mide 40 mg/kg for four days [5]. Total body irradiation
(1.5cGY x twice a day) and Cyclophosphamide (60 mg/
kg/day for two days) was used in patients with Philadel-
phia positive Acute Lymphoblastic Leukemia and those
with one-antigen mismatch donors.
In Aplastic anaemia rabbit anti-thymocyte globulin
(10 mg/kg/day for three days) and Cyclophosphamide
(50 mg/kg/day for four days) was used. Patients with
Fanconi’s anaemia received conditioning with Fludara-
bine (30 mg/kg/day for five days), Cyclophosphamide
(300 mg/m2 for four days) and rabbit anti-thymocyte
globulin (3.75 mg/kg/day for three days).
Infectious disease prophylaxis
Patients were admitted in protective isolation equipped
with HEPA filter, positive pressure and laminar airflow
ventilation. Standard prophylaxis with Ciprofloxacin
(500 mg twice daily or 20-30 mg/kg/two divided doses),
Fluconazole (200 mg once daily or 6 mg/kg/day) and
Valaciclovir (500 mg twice daily or 10 mg/kg/twice daily)
was started in all patients on day-5. All patients were
provided with neutropenic diet.
Graft versus host disease prophylaxis
Intravenous Cyclosporine was started on day-1 and doses
were adjusted according to drug levels. Optimum adult
range was 200-250 ng/dl. For paediatric patients, levels
were maintained between 150-200 ng.dl. Methotrexate
15 mg/m2 was administered on day +1, while 10 mg/m2
was given on days +3 +6. Irradiated and leukocyte
reduced blood products were used throughout admission
as well as in the post-transplant period
Assessment of engraftment
Absolute neutrophil count of ≥500 x 109/L for three con-
secutive days was considered engraftment in all patients.
For further confirmation, post-transplant chimerism studies
of patient and donor were carried out at day+90.
Statistical analysis
All the data was entered on SPSS version 19 (SPSS Inc.,
Chicago, IL, USA) for computing means, standard devi-
ation and range of all descriptive variables. Survival was
calculated from the date of transplant to death or last
follow-up according to Kaplan-Meier analysis methods.
Results
From April 2004 till September 2011, n = 97 patients
underwent allogeneic stem cell transplant procedure for
various haematological disorders. Four patients received
stem cells from complete matched parent donor while
all others had a HLA compatible sibling donor. There
were n = 70 (72.2%) males and n = 27 (27.8%) females.
N = 44 (45.4%) patients belonged to the paediatric popu-
lation while n = 53 (54.6%) were adults. Median age ± SD
was 17 years ±12.5 years (range: 2–53 years).
Most common indications for transplant were idio-
pathic aplastic anaemia in n = 34 (35%), followed by β-
Thalassemia major in n = 21 (21.6%) and chronic myeloid
leukemia in n = 11 patients (Figure 1). For acute lympho-
blastic leukemia, n = 4 were positive for Philadelphia
chromosome, n = 3 had disease relapse. Three patients
with acute myeloid leukemia (AML) were in complete re-
mission at the time of transplant. Procedure for relapsed
AML was done in n = 5 patients. There were n = 2
patients with high risk disease (one patient developed
AML preceded by myelodysplastic syndrome while one
had Monosomy 8). At the time of admission, n = 4
patients (4.1%) were hepatitis C reactive. All four patients
were suffering from severe aplastic anaemia therefore
hepatitis C treatment at that point in time was not pos-
sible due to thrombocytopenia.
Seventeen patients (17.5%) received only bone marrow
as a source of stem cells. Peripheral blood was used in
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n= 50 patients (51.5%) while n = 30 (30.9%) received
both bone marrow and peripheral blood. Primary graft
failure was seen in 2.06%. All other patients (n = 95;
98%) achieved successful engraftment. Median time ± SD
to neutrophil recovery was 13 ± 3.1 days (range: 9–
22 days) while for platelet recovery was 17 ± 3.4 days
(range: 13 to 36 days). Secondary graft failure occurred
in n = 2 patients with aplastic anaemia and n = 1 patient
with β-thalassemia major. Seven patients with Aplastic
anaemia expired due to E-Coli sepsis (n = 6) and Fusar-
ium infection (n = 1).
Overall incidence of graft versus host disease (GvHD)
in our patients was 34%. Out of these, n = 18 (18.6%)
developed acute GvHD (grade I-IV) whereas n = 15
(15.5%) had chronic GvHD (limited –n= 2 and extensive
– n= 13). Frequency of GvHD according to diagnosis is
shown in Figure 2.
Other post-transplant non infective complications
were veno-occlusive disease in n = 4 (4.1%), haemor-
rhagic cystitis in n = 2 (2.06%), cyclosporine induced
thrombotic microangiopathy in n = 1 patient and venous
thromboembolism in n= 2 patients. In one of the patient
with haemorrhagic cystitis, the cause was BK virus infec-
tion. He responded to supportive treatment resulting in
complete recovery.
Other post-transplant infective complications included
fungal infections in n = 2 patients, herpes zoster in n = 6
patients and cytomegalovirus infection in n = 1 patient.
Transplant related mortality was seen in n = 14
patients. Causes of mortality included sepsis in n = 8
patients. Mortality due to single organism infection (E
coli) was seen in n = 4 and Fusarium was seen in n = 1
patient. Others were infected with multiple organisms
which included E Coli and Pseudomonas (n = 1) Ecoli,
acinetobacter and alcaligenes (n = 2). Other causes were
fulminant hepatic failure (1), adult respiratory distress
syndrome (1), graft failure (1), GvHD (2) and condition-
ing related mortality (1).
At the end of 5 years, the overall survival (OS) of allo-
geneic transplant in our study was 71.3% with a mean
survival time of 51.2 ± 3.3 months. In Aplastic anaemia
the overall survival was 71% with a mean survival time
of 51 ± 5.8 months. For β thalassemia major patients, the
mean survival time was 49 ± 4.9 months and overall sur-
vival was 81.8%. In chronic myeloid leukemia, OS was
63.6% with a mean survival time of 45.8 ± 9.9 months.
Lastly, in patients with acute leukemia, the overall sur-
vival was 66.7%. The disease wise survivals are shown in
Figure 3 and 4.
Discussion
For many congenital and acquired haematological disor-
ders, haematopoietic stem cell transplant has become an
established procedure. The European group for Blood
and Bone Marrow transplantation survey in 2009
reported 41% allogeneic transplants from six hundred
and twenty four centres (43 countries). The main indica-
tions were leukemias, lymphomas, solid tumours and
non-malignant disorders [6]. These results are in sharp
contrast with our centre where we have done allogeneic
transplants in non-malignant disorders like aplastic an-
aemia and β-Thalassemia major.
Figure 1 Indications for allogeneic stem cell transplant.
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The Eastern Mediterranean Bone Marrow Transplant-
ation group has reported acute leukemias, bone marrow
failure syndromes and haemoglobinopathies as the most
common indications [7]. A similar study done in 2007
from our country also shows results compatible with
ours [8]. The most prevalent genetically transmitted
haematological disorder in Pakistan is β- Thalassemia
major with a carrier rate of 5-8%. Around 5,000 children
are diagnosed each year [9] and safe transfusion prac-
tices along with iron chelation therapy are very expen-
sive in our country therefore transplant remains to be
the only available curative option.
Currently, peripheral blood cells are increasingly re-
placing bone marrow as a source of stem cells in
Figure 2 Incidence of GvHD according to diagnosis.
95%CI
Figure 3 Overall survival in allogeneic stem cell transplant n=97.
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allogeneic stem cell transplant[10].We have also followed
the same protocol except in aplastic anaemia where
combination of bone marrow as well as peripheral blood
progenitor cells was used in order to decrease the inci-
dence of graft versus host disease.
Primary graft failure after haematopoietic stem cell
transplantation is a life threatening complication, the
reported incidence being as high as 11% [11]. Our study
has reported an incidence of 2% which is much lower
when compared to international literature. The largest
study to date done by Schriber J et al. [12] quotes high-
est frequency in match unrelated donor transplants. No
donor registry exists in our country therefore at the mo-
ment we are performing match related transplants as a
result of which we have decreased incidence of graft
failure.
Graft versus host disease remains to be one of the
major complications of allogeneic bone marrow trans-
plant. Despite HLA identity between patient and donor
approximately 40% of recipients develop acute systemic
GvHD [13]. None of our patients who received bone
marrow only as a source of stem cells developed GvHD.
We are not using T-cell depleted grafts therefore the in-
cidence was highest with using only peripheral blood as
a source of stem cells. Nevertheless, data from our
centre has shown a lower incidence of GvHD as com-
pared to national and international literature.
Neutropenia in post-transplant patients gives rise to
bacterial infections. The percentage of gram negative
organisms causing blood stream infections has decreased
to 30% in the last two decades. Gram positive organisms
now attribute to 70% of infections [14]. However, in our
part of the world the trend remains unchanged as major
pathogens are still gram negative bacteria most com-
monly E coli seen in our study as well as other studies
from our country.
The survival of patients with beta thalassemia major
has improved with regular blood transfusions and iron
chelation therapy. However, definitive long term cure
has been established through stem cell transplant. The
centre with the largest experience is that of Lucarelli and
his colleagues at Pesaro, Italy where survival has been
reported as 73% [15]. Our study including all three
groups of thalassemic patients has also shown similar
results.
The recommended treatment for idiopathic aplastic
anaemia is allogeneic stem transplant provided an
HLA matched sibling donor is available. Survival rates
have been reported as high as 85-90%. Wang W et al.
has reported 74.1% [16] while Eapen M et al. [17]
have reported an overall survival of 76% by using
bone marrow only as a source of stem cells. In our
group of patients, bone marrow as well as peripheral
blood was used as a combination for the source of
95%CI
Figure 4 Overall survival according to diagnosis n=97.
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stem cells with 71% survival which is equivalent to
international literature.
Chen Y et al. in 2011 reported an overall survival of
73.4% in n= 104 patients undergoing stem cell transplants
for haematological malignancies [18]. An overall survival
of 48% was found in patients undergoing allogeneic stem
cell transplant in first complete remission (CR1) for acute
myeloid leukemia. Our study shows a similar figure (OS:
50%) in AML. However, our cohort consisted of patients
undergoing transplants in CR1 as well relapsed acute mye-
loid leukemia.
Historically, allogeneic stem cell transplant for acute
lymphoblastic leukemia (ALL) in CR1 has been reserved
for patients with high risk disease, such as those with
Philadelphia positive ALL (ph+ ve ALL) [19]. Our cohort
included n=4 patients with ph+ ve ALL while n = 3
patients had T-cell ALL. The overall survival in these
patients was 71.4%. However the overall survival in
n= 4 ph+ ve patients was 75%. Although the sample size
is small, this frequency is similar to GOELAMS trial [20]
but inferior to other studies conducted for ALL.
Haemopoietic stem cell transplant in chronic myeloid
leukemia is now mostly indicated for patients who de-
velop resistance to tyrosine kinase inhibitors [21].
Boehm A et al. in 2011 has reported an overall survival
of 62% with a better outcome seen in chronic phase
CML as compared to accelerated CML [22]. In our
group of n = 11 patients, 2 patients had accelerated CML
while others were in the chronic phase. The overall sur-
vival however, is in concordance with the compared
study i.e. 63.6%.
Overall survival in our cohort was 71%. More than half
of the transplants were performed for non-malignant
diseases like Thalassemia Major and Aplastic Anaemia
(n = 55). The median age of these n = 55 patients was
18 ± 12.6 years (range: 2–53 years). Therefore, a better
overall survival in our patients can be attributed to
transplant for non-malignant diseases, match related
stem cells and younger age group.
The government of Pakistan has spent 0.6-1.1% of its
GDP and 5.1% - 11.6% of its developmental expenditure on
health over the last 10 years. The account of private sector
health services is not included in this figure. Pakistan’s GDP
in 2010 was reported as $161.99 billion (23) and average
household income ranges from $1200-$1500 per annum.
The cost of standard uncomplicated stem cell transplant
ranges from $21,000 - $26,000, a figure affordable by hand-
ful of patients therefore n=68 (70%) of our transplants
were funded completely and/or partially by the hospital,
non-governmental organisations and philanthropists.
Conclusion
Allogeneic stem cell transplant remains to be the only
curative therapy in many potentially fatal haematological
diseases and is now being offered as a treatment option
in a developing country like ours. Aplastic anaemia and
β-thalassemia major were the common indications for
the procedure. Frequency of acute and chronic GvHD
was lower as compared to international literature. The
overall survival in our study was approximately 71%.
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